Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study..

N Engl J Med. 2005 Jul 7;353(1):33-45.

2.

Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Samuelson B, Chai-Adisaksopha C, Garcia D.

J Thromb Thrombolysis. 2015 Nov;40(4):474-9. doi: 10.1007/s11239-015-1218-2. Review.

PMID:
25894476
3.

Anagrelide: what was new in 2004 and 2005?

Petrides PE.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. Review.

PMID:
16810615
4.

[Treatment of essential thrombocythemia].

Alvarez-Larrán A, Cervantes F, Besses C.

Med Clin (Barc). 2013 Sep 21;141(6):260-4. doi: 10.1016/j.medcli.2013.01.016. Epub 2013 Mar 13. Review. Spanish.

PMID:
23490491
5.

Anagrelide: a review of its use in the management of essential thrombocythaemia.

Wagstaff AJ, Keating GM.

Drugs. 2006;66(1):111-31. Review.

PMID:
16398570
6.

Therapeutic options for essential thrombocythemia and polycythemia vera.

Solberg LA Jr.

Semin Oncol. 2002 Jun;29(3 Suppl 10):10-5. Review.

PMID:
12096352
7.

[Primary thrombocythemia: diagnosis and therapy].

Petrides PE.

Med Klin (Munich). 2006 Aug 15;101(8):624-34. Review. German.

PMID:
16896569
8.

Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.

Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Brière J.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:149-60. Review.

PMID:
8951786
9.
10.

Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.

Barbui T, Finazzi G.

Curr Hematol Rep. 2003 May;2(3):248-56. Review.

PMID:
12901347
11.

[Treatment of essential thrombocythemia].

Costello R, O'Callaghan T, Sébahoun G.

Rev Med Interne. 2005 Dec;26(12):947-55. Epub 2005 Aug 11. Review. French.

PMID:
16122842
12.

Treatment of polycythaemia vera and essential thrombocythaemia.

Tefferi A, Silverstein MN.

Baillieres Clin Haematol. 1998 Dec;11(4):769-85. Review.

PMID:
10640216
13.

Indications for lowering platelet numbers in essential thrombocythemia.

Barbui T.

Semin Hematol. 2003 Jan;40(1 Suppl 1):22-5. Review.

PMID:
12682878
14.

Management of patients with essential thrombocythemia: current concepts and perspectives.

Briere J, Guilmin F.

Pathol Biol (Paris). 2001 Mar;49(2):178-83. Review.

PMID:
11317966
15.

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.

Petrides PE.

Expert Opin Pharmacother. 2004 Aug;5(8):1781-98. Review.

PMID:
15264993
16.

Update on diagnosis and management of essential thrombocythemia.

Gisslinger H.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):430-6. Review.

PMID:
16810619
17.

A critical review of anagrelide therapy in essential thrombocythemia and related disorders.

Dingli D, Tefferi A.

Leuk Lymphoma. 2005 May;46(5):641-50. Review.

PMID:
16019501
18.

Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.

Michiels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A, Thiele J.

Leuk Lymphoma. 2000 Jan;36(3-4):239-53. Review.

PMID:
10674896
19.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

20.

Pharmacotherapy of essential thrombocythemia.

Gangat N, Tefferi A.

Expert Opin Pharmacother. 2008 Jul;9(10):1679-85. doi: 10.1517/14656566.9.10.1679 . Review.

PMID:
18570601

Supplemental Content

Support Center